Disciplined Investments’s Nektar Therapeutics NKTR Stock Holding History

Disciplined Investments’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	1504
2022 Q1	$0	Buy	+1	New	+$148	﹤0.01%	1525

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Disciplined Investments's NKTR Position: Q2 2022 in Review

Disciplined Investments sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 1 share.

Disciplined Investments first reported a position in NKTR in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 228 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Disciplined Investments reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
Disciplined Investments sold 1 Nektar Therapeutics share in Q2 2022.
Disciplined Investments first reported a position in Nektar Therapeutics in Q1 2022 and held it in 1 quarter.
Disciplined Investments's Nektar Therapeutics position peaked at $0 in Q1 2022.
228 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Disciplined Investments's 13F filing for Q2 2022, filed 9 Aug 2022.